The company will soon begin human trials for their mRNA-based vaccine, according to information posted to the National Institute of Health’s (NIH) clinical trials database last week. Moderna is seeking 56 individuals, aged 18 to 50 and who are HIV-negative, for the trial, which is estimated to begin on August 19 and conclude in spring 2023. Moderna is also reportedly developing an influenza vaccine based on the same technology.